[1] ANGIOLILLO D J， BATES E R. Platelet inhibitor therapy： Current perspectives and emerging novel agents： Introduction .Am Heart J， 2008， 156(2)：1-2.
[2] CHENG H. New developments in antiplatelet agents.Adv Cardiovasc Dis（心血管病学进展），2009，30(1)：105-109.
[3] CHENG D，LIU Y，LIU D K， et al. Synthesis and activity evaluation of some novel derivatives of 4， 5， 6， 7-tetrahydrothieno -pyridine containing substituted piperazine or piperidine. .Chin Pham J(中国药学杂志)， 2009， 44(22)：1752-1754.
[4] CATTANEO， MARCO.The platelet P2Y12 receptor for adenosine diphosphate： Congenital and drug-induced defects .Blood， 2011， 117(7)：2102.
[5] SONG J H， DU X L. A novel oral antiplatelet activation and aggregation agent： Prasugrel . Chin Pham J(中国药学杂志)， 2010， 45(17)：1357-1358.
[6] BRANDT J T，PAYNE C D，WIVIOTT S D，et al.A comparison of prasugrel and clopidogrel loading doses on platelet function：Magnitude of platelet inhibition is related to active metabolite formation.Am Heart J， 2007，153：（1）66.e9-e16.
[7] MONTALESCOT G，WIVIOTT S D，BRAUNWALD E，et al.Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITION-TIMI38)： double—blind， randomized controlled tria1.Lancet，2009，373（9665）：723-731.
[8] BHATT D L，LINCOFF A M，GIBSON C M，et al．Intravenous platelet blockade with cangrelor during PCI.N Engl J Med，2009，361(24)：2330-2341.
[9] HARRINGTON R A， STONE G W，MCNULTY S，et al.Platelet inhibition with cangrelor in patients undergoing PCI.N Engl J Med，2009，361(24)：2318-2329.
JAMES S， AKERBLOM A，CANNON C P，et al.Comparison of ticagrelor， the first reversible oral P2Y12 receptor antagonist， with clopidogrel in patients with acute coronary syndromes： Rationale， design， and baseline characteristics of the PLATelet inhibition and patient outcomes (PLATO) trial.Am Heart J，2009，157(4)：599-605.
WALLENTIN L. P2Y12 inhibitors： Differences in properties and mechanism of action and potential consequences for clinical use . Eur Heart J， 2009， 30（16）：1964-1977.
LIEU H D， CONLEY P B， ANDRE P， et al. Initial intravenous experience with PRT060128 (PRT128)， an orally-available， direct-acting， and reversible P2Y12 inhibitor. J Thromb Haemost， 2007，5(suppl 2)： P-T-292.
LEONARDI S， RAO S V， HARRLINGTON R A， et al.Rationale and design of the randomized， double-blind trial testing INtraveNous and Oral administration of elinogrel， a selective and reversible P2Y12-receptor inhibitor， versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI).Am Heart J，2010，160(1)：65-72.
Portola Pharmaceuticals. A Phase 2 Safety and Efficacy Study of PRT060128， a Novel Intravenous and Oral P2Y12 Inhibitor， in Non-Urgent PCI (INNOVATE-PCI) . http：//clinicaltrials.gov/ct2/ show/ NCT00- 751231.
GURBEL P A，BLINDON K P，ANTONINO M J，et al.The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to cyp 2c19*2 genotype： First experience in patients. J Thromb Haemost， 2010，8（1）：43-53.
BERGER J S， ROE M T， GIBSON C M， et al.Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel， a direct-acting and reversible P2Y12 ADP-receptor antagonist， before primary percutaneous intervention in patients with ST-elevation myocardial infarction： The Early Rapid ReversAl of Platelet ThromboSis with Intravenous Elinogrel before PCI to Optimize REperfusion in Acute Myocardial Infarction (ERASE MI) pilot trial .Am Heart J， 2009， 158(6)：998-1004.
RAO S V.A randomized， double-blind， active controlled trial to evaluate intravenous and oral PRT060128 (elinogrel)， a selective and reversible P2Y12 receptor inhibitor vs clopidogrel as a novel antiplatelet therapy in patients undergoing nonurgent percutaneous coronary interventions. in Proceedings of the European Society of Cardiology Congress， Stockholm， Sweden， 2010.
HIRSCHLER B.UPDATE 1-Novartis， Portola heart drug moves to final tests . Adds comment from doctors portolaceo，stockholm，Reuters， 2008-08-30.
DERIAN C K，DAMIANO B P， ADDO M F，et al.Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates.J Pharmacol Exp Ther ， 2003，304(2)：855-861 .
CHACKALAMANNIL S，WANG Y，GREENLEE W J，et al.Discovery of a novel， orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J Med Chem， 2008， 51（11）：3061-3064.
BECKER R C， MOLITERNO D J， JENNINGS L K， et al .Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention： A randomized， double-blind， placebo-controlled phase II study.Lancet ，2009，373（9667）：919-928.
GOTO S， YAMAGUCHI T， IKEDA Y， et al .Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome. J Atheroscler Thromb， 2010，17(2)：156-164 .
Schering-Plough .Trial to Assess the Effects of SCH 530348 in Preventing Heart Attack and Stroke in Patients With Acute Coronary Syndrome (TRA CER) (Study P04736AM3). http ：//clinicaltrials. gov /ct2/show/NCT00527943.
Schering-Plough .Trial to Assess the Effects of SCH 530348 in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2°P-TIMI 50) (Study P04737AM3).http：//clinicaltrials. gov/ ct2/show/NCT00526474.
Eisai Inc. Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects with Acute Coronary Syndrome. http：// clinicaltrials. gov/ ct2/ show/NCT00548587.
Eisai Inc .Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects with Coronary Artery Disease. http：// clinicaltrials. gov/ ct2/ show/NCT00312052.
O'DONOGHUE M L， BHATT D L， WIVIOTT S D， et al .Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes： The lessons from antagonizing the cellular effects of Thrombin-Acute Coronary Syndromes Trial.Circulation， 2011， 123(17)：1843-1853．
HENNERICI M G， BOTS M L， FORD I， et al .Rationale， design and population baseline characteristics of the PERFORM Vascular Project： An ancillary study of the Prevention of cerebrovascular and cardiovascular Events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) trial.Cardiovasc Drugs Ther， 2010， 24(2)： 175-180.
FIESSINGER J N， BOUNAMEAUX H， CAIROLS M A， et al. Thromboxane antagonism with terutroban in peripheral arterial disease： The TAIPAD study . J Thromb Haemost， 2010， 8(11)：2369-2376.
Shinobara. The results of CSPS， a large-scale clinical trial of cilostazol in preventing recurrent stroke， presented at American Stroke Association′s International Conference. San Antonio， on February 26， 2010.
ZAFAR M U， IBANEZ B， CHOL B G， et al. A new oral antiplatelet agent with potent antithrombotic properties： Comparison of DZ-697b with clopidogrel in a randomized phaseⅠstudy . J Thromb Haemost， 2010， 103(1)：205-212.